Outcomes reported | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Therapy | Published study | Primary outcome | Radiologic outcome | Follow-up | BASDAI | BASFI | BASMI | QoL | EMS | Fatigue | CRP/ ESR |
Infliximab | 50% improvement in BASDAI at week 12 | mSASSS | 5 years | x | x | x | x | x | Â | x | |
Infliximab | Marzo-Ortega and colleagues [101] | Change in BASDAI at weeks 4, 10, 30 | MRI inflammatory lesions | 30 weeks | x | x | Â | x | x | Â | x |
Infliximab | ASAS 20 at week 24 | mSASSS | 8 years | x | x | x | x | x | x | x | |
Etanercept | Davis and colleagues [103–105], van der Heijde and colleagues [84] | ASAS 20 at week 12 | mSASSS | 16 years | x | x | x |  | x |  | x |
Etanercept | ASAS 20 at week 12 | mSASSS | 8 years | x | x | x | Â | x | Â | x | |
Adalimumab | van der Heijde and colleagues [108] | ASAS 20 at week 12 | NA | 24 weeks | x | x | x | x | x | Â | x |
Golimumab | Inman and colleagues [109] | ASAS 20 at week 14 | NA | 24 weeks | x | x | x | x | x | Â | x |